Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Return on Sales (2016 - 2025)

Voyager Therapeutics' Return on Sales history spans 11 years, with the latest figure at 1.79% for Q4 2025.

  • For Q4 2025, Return on Sales rose 370.0% year-over-year to 1.79%; the TTM value through Dec 2025 reached 2.97%, down 175.0%, while the annual FY2025 figure was 2.97%, 215.0% down from the prior year.
  • Return on Sales for Q4 2025 was 1.79% at Voyager Therapeutics, up from 2.09% in the prior quarter.
  • Across five years, Return on Sales topped out at 15.23% in Q4 2022 and bottomed at 32.4% in Q1 2022.
  • The 5-year median for Return on Sales is 3.66% (2021), against an average of 5.94%.
  • The largest annual shift saw Return on Sales tumbled -2847bps in 2022 before it skyrocketed 3322bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.18% in 2021, then surged by 8353bps to 15.23% in 2022, then plummeted by -96bps to 0.63% in 2023, then tumbled by -977bps to 5.49% in 2024, then soared by 67bps to 1.79% in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Return on Sales are 1.79% (Q4 2025), 2.09% (Q3 2025), and 6.42% (Q2 2025).